Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression.

Scientific reports·2020
Same author

Ken Fearon.

Cell metabolism·2016
Same author

In vitro assessment of the combined effect of eicosapentaenoic acid, green tea extract and curcumin C3 on protein loss in C2C12 myotubes.

In vitro cellular & developmental biology. Animal·2016
Same author

Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia.

Nutrition (Burbank, Los Angeles County, Calif.)·2014
Same author

Attenuation of muscle wasting in murine C2C 12 myotubes by epigallocatechin-3-gallate.

Journal of cachexia, sarcopenia and muscle·2014
Same author

Role of β-adrenergic receptors in the oral activity of zinc-α2-glycoprotein (ZAG).

Endocrinology·2012

Related Experiment Video

Updated: Jun 10, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

Reversing cachexia.

Michael J Tisdale1

  • 1Nutritional Biomedicine, School of Life and Health Sciences, Aston University, Birmingham B4 7ET, UK. m.j.tisdale@aston.ac.uk

Cell
|August 21, 2010
PubMed
Summary
This summary is machine-generated.

Cancer cachexia, a life-threatening condition, can be treated by blocking the activin type-2 receptor (ActRIIB). This approach reversed muscle wasting and increased lifespan in mouse models, offering new therapeutic hope.

More Related Videos

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

Related Experiment Videos

Last Updated: Jun 10, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
09:12

Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery

Published on: March 27, 2018

Area of Science:

  • Oncology
  • Muscle Physiology
  • Molecular Biology

Background:

  • Cancer cachexia is a severe condition with limited treatment options.
  • Muscle wasting affects skeletal and cardiac muscles, impacting patient survival.
  • Identifying novel therapeutic targets for cachexia is crucial.

Discussion:

  • The study identifies the activin type-2 receptor (ActRIIB) as a key mediator of cancer cachexia.
  • Blocking ActRIIB with a decoy receptor demonstrated efficacy in preclinical models.
  • This intervention reversed muscle atrophy and improved survival rates.

Key Insights:

  • Targeting ActRIIB offers a promising strategy for combating cancer cachexia.
  • Decoy receptor therapy effectively mitigates muscle wasting in cachexia models.
  • Increased lifespan observed in treated mice highlights therapeutic potential.

Outlook:

  • Further research into ActRIIB inhibition could lead to new cancer therapies.
  • Clinical trials may explore decoy receptor efficacy in human cancer patients.
  • This finding opens avenues for regenerative medicine in oncology.